Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06147843

French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis

Led by University Hospital, Limoges · Updated on 2024-11-25

1000

Participants Needed

7

Research Sites

262 weeks

Total Duration

On this page

Sponsors

U

University Hospital, Limoges

Lead Sponsor

N

National Research Agency, France

Collaborating Sponsor

AI-Summary

What this Trial Is About

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Studies have shown the importance of weight loss at the time of diagnosis and during the progression of the disease. However, the pathophysiological mechanisms behind weight loss remain unknown. Identifying these mechanisms could make it possible to propose an effective therapeutic strategy against weight loss for ALS patients, which could improve their survival and quality of life. In this context, the investigators are proposing an innovative multidisciplinary project aimed at structuring a large Franco-German cohort to identify the markers associated with weight loss in ALS. Participants will undergo high quality standard care for ALS patients. In addition, participants will be asked to respond different questionnaires and blood samples will be taken for analysis to identify biological markers.

CONDITIONS

Official Title

French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with definite, probable, probable laboratory-supported, or possible ALS according to El Escorial revised and Gold Coast criteria at the time of diagnosis
  • Incident ALS cases identified and followed-up in designated ALS and Motor Neuron Diseases Referral Centres in France and Germany
  • Signed informed consent form
  • Adults aged over 18 years
Not Eligible

You will not qualify if you...

  • Unable to understand the protocol requirements
  • Unable to sign or comprehend the informed consent form due to cognitive issues
  • Refusal to accept Riluzole therapy during follow-up

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

CHU de Lille

Lille, France, 59037

Not Yet Recruiting

2

Limoges University Hospital

Limoges, France, 87042

Actively Recruiting

3

Hôpital de la Timone

Marseille, France, 13005

Not Yet Recruiting

4

Hôpital Gui Chauliac

Montpellier, France, 34295

Not Yet Recruiting

5

CHU de Nice

Nice, France, 06001

Not Yet Recruiting

6

Hôpital de la Pitié Salpêtrière

Paris, France, 75013

Not Yet Recruiting

7

CHU de Tours

Tours, France, 37044

Not Yet Recruiting

Loading map...

Research Team

P

Philippe COURATIER, Pr

CONTACT

A

Andrea ERAZO ALEMAN, Dr

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here